First-generation EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib have significant
activity in NSCLC patients with activating EGFR mutations. However, EGFR-TKI resistance …

Lung cancer is a leading cause of cancer mortality worldwide. In tumors, the important role
of noncoding RNA regulatory networks has been more and more reveal. EGFR has been …

Abstract Epidermal Growth Factor Receptor (EGFR) signaling and EGFR mutations play key
roles in cancer pathogenesis, particularly in the development of drug resistance. For the∼ …

Background EGFR mutation is a strong predictor of efficacy of epidermal growth factor
receptor tyrosine kinase inhibitor (EGFR-TKIs) therapy in advanced non-small cell lung …

Background Non-small-cell lung cancer (NSCLC) patients with activating epidermal growth
factor receptor (EGFR) mutations may exhibit primary resistance to EGFR tyrosine kinase …

Non-small cell lung cancer (NSCLC) patients with EGFR mutations initially respond well to
EGFR tyrosine kinase inhibitors (TKIs) but eventually exhibit acquired or innate resistance to …

Chemoresistance is one of the most important biological elements affecting the progression
and prognosis of cancer. Long non‑coding RNAs (lncRNAs) are important regulators and …

Lung cancer is the leading cause of cancer‐associated death, and non‐small cell lung
cancer (NSCLC) accounts for 85% of all lung cancer cases. Many drugs have been used to …

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib,
have been established as first-line treatments for non-small cell lung cancer (NSCLC) …

Long non‑coding RNAs (lncRNAs) have been reported to be involved in the physiological
and pathological processes of tumor pathogenesis, including epithelial‑mesenchymal …